42
Participants
Start Date
June 1, 2022
Primary Completion Date
April 30, 2027
Study Completion Date
October 31, 2027
Sargramostim
Sargramostim is a granulocyte macrophage colony stimulating factor that will be administered at a dose of 250 mcg/m2 per day subcutaneously, 5 days/week, for 24 weeks
Saline - placebo comparator
Saline will be administered subcutaneously, 5 days/week, for 24 weeks
RECRUITING
University of Colorado Anschutz Medical Campus, Aurora
Collaborators (1)
National Institute on Aging (NIA)
NIH
Alzheimer's Association
OTHER
Partner Therapeutics, Inc.
INDUSTRY
University of Colorado, Denver
OTHER